{"id":"arry-502-crth2-antagonist-oral","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARRY-502 works by selectively antagonizing the CRTh2 receptor, a key player in the inflammatory response. This action helps to reduce inflammation and alleviate symptoms associated with allergic diseases. By targeting CRTh2, ARRY-502 aims to provide a novel therapeutic approach for treating conditions characterized by excessive inflammation.","oneSentence":"Blocks CRTh2 receptor to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:19.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT01561690","phase":"PHASE2","title":"A Study of ARRY-502 in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04-02","conditions":"Asthma","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARRY-502, CRTh2 antagonist; oral","genericName":"ARRY-502, CRTh2 antagonist; oral","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks CRTh2 receptor to reduce inflammation. Used for Allergic rhinitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}